BioPorto A/S (CPH: BIOPOR)
Denmark
· Delayed Price · Currency is DKK 1.850
-0.016 (-0.86%)
Sep 25, 2024, 4:59 PM CET
BioPorto Revenue
BioPorto had revenue of 9.20M DKK in the quarter ending June 30, 2024, with 18.74% growth. This brings the company's revenue in the last twelve months to 33.83M, up 13.71% year-over-year. In the year 2023, BioPorto had annual revenue of 30.96M with 6.87% growth.
Revenue (ttm)
33.83M
Revenue Growth
+13.71%
P/S Ratio
20.71
Revenue / Employee
1.25M
Employees
29
Market Cap
792.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 30.96M | 1.99M | 6.87% |
| Dec 31, 2022 | 28.97M | 4.72M | 19.44% |
| Dec 31, 2021 | 24.25M | 1.05M | 4.53% |
| Dec 31, 2020 | 23.20M | -3.42M | -12.84% |
| Dec 31, 2019 | 26.62M | 606.00K | 2.33% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk A/S | 258.00B |
| Coloplast A/S | 26.30B |
| Genmab A/S | 19.02B |
| Zealand Pharma A/S | 367.97M |
| Demant A/S | 22.84B |
| H. Lundbeck A/S | 20.67B |
| H. Lundbeck A/S | 20.67B |
| ALK-Abelló A/S | 5.18B |
BioPorto News
- 7 weeks ago - BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024 - GlobeNewsWire
- 2 months ago - BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting - GlobeNewsWire
- 2 months ago - BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms - GlobeNewsWire
- 2 months ago - BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo - GlobeNewsWire
- 3 months ago - BioPorto confirms market acceptance of NGAL products with US standing order. - GlobeNewsWire
- 3 months ago - Changes of number of shares and votes in BioPorto A/S - GlobeNewsWire
- 3 months ago - Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S. - GlobeNewsWire
- 3 months ago - BioPorto A/S initiates a private placement of 50,000,000 new shares at market price. - GlobeNewsWire